JNJ Stock Recent News

Shares of Johnson & Johnson  JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine. “At Johnson & Johnson, we are committed to transforming care for the millions of people worldwide living with neuropsychiatric and neurodegenerative disorders,” said Joaquin Duato, Chairman an.

I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top teams like the Dodgers now pair consistency with big spending. Similarly, investors need financially strong, wide-moat stocks with rising cash flow, durable dividends, and resilience. Moreover, I'm targeting stocks with these traits: reliable growth, low payout ratios, and recession-proof models. Like championship teams, they're built to win over time.

Major U.S. equities indexes finished the first trading day of the second quarter mixed.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies' shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by approximately 0.8% with approximately $0.7 billion in incr.

Shares of Johnson & Johnson (JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m.

The S&P 500 experienced volatility on Tuesday and was in the green. Investors were awaiting clarity from US President Donald Trump regarding tariff policy, and weaker-than-expected economic data also put pressure on Wall Street.

Verizon is the only Dow Dog currently meeting the ideal of annual dividends from $1K invested exceeding its single share price. Analysts forecast net gains of 13.06% to 37.60% for the top-ten Dow Dogs by April 2026, with NVIDIA leading. The five lowest-priced Dow Dogs are expected to deliver 39.38% more gain than the general top ten by March 2026.

Johnson & Johnson (NYSE:JNJ) shares moved almost 5% lower after a US bankruptcy judge rejected its $10 billion settlement proposal which sought to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston, dismissed the bankruptcy claim filed by J&J subsidiary Red River Talc, citing flaws in the voting process for personal injury claimants.